LSE - Delayed Quote GBp

Genus plc (GNS.L)

2,085.00
-20.00
(-0.95%)
As of 11:12:43 AM GMT+1. Market Open.
Currency in GBP All numbers in thousands
Download
Breakdown
TTM
6/30/2024
6/30/2023
6/30/2022
6/30/2021
Total Revenue
668,800
668,800
689,700
593,400
574,300
Cost of Revenue
490,100
490,100
502,200
445,500
420,400
Gross Profit
178,700
178,700
187,500
147,900
153,900
Operating Expense
147,700
147,700
143,500
96,500
102,900
Operating Income
31,000
31,000
44,000
51,400
51,000
Net Non Operating Interest Income Expense
-18,300
-18,300
-14,300
-6,200
-5,000
Pretax Income
5,500
5,500
39,400
48,400
55,800
Tax Provision
3,100
3,100
7,600
11,700
9,000
Net Income Common Stockholders
7,900
7,900
33,300
40,900
47,300
Diluted NI Available to Com Stockholders
7,900
7,900
33,300
40,900
47,300
Basic EPS
0.12
0.12
0.51
0.62
0.73
Diluted EPS
0.12
0.12
0.51
0.62
0.72
Basic Average Shares
65,686
65,686
65,557
65,395
65,108
Diluted Average Shares
66,174
66,174
65,998
65,714
65,662
Total Operating Income as Reported
6,400
6,400
40,500
49,400
47,700
Rent Expense Supplemental
100
100
100
100
100
Total Expenses
637,800
637,800
645,700
542,000
523,300
Net Income from Continuing & Discontinued Operation
7,900
7,900
33,300
40,900
47,300
Normalized Income
26,350
26,350
35,869
42,414
49,926.80
Interest Income
3,900
3,900
1,100
400
400
Interest Expense
21,300
21,300
14,300
5,700
4,500
Net Interest Income
-18,300
-18,300
-14,300
-6,200
-5,000
EBIT
26,800
26,800
53,700
54,100
60,300
EBITDA
73,700
73,700
97,300
93,100
95,400
Reconciled Cost of Revenue
490,100
490,100
502,200
445,500
420,400
Reconciled Depreciation
46,900
46,900
43,600
39,000
35,100
Net Income from Continuing Operation Net Minority Interest
7,900
7,900
33,300
40,900
47,300
Total Unusual Items Excluding Goodwill
-24,600
-24,600
-3,500
-2,000
-3,300
Total Unusual Items
-24,600
-24,600
-3,500
-2,000
-3,300
Normalized EBITDA
98,300
98,300
100,800
95,100
98,700
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-6,150
-6,150
-931
-486
-673.20
6/30/2021 - 7/6/2000

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

FUM.L Futura Medical plc
9.27
+5.10%
 
F6T.DU Fate Therapeutics Inc
0.8106
-5.28%
 
1CVAC.MI CureVac N.V.
3.0800
+0.79%
 
ABRT.CN Albert Labs International Corp.
0.0050
0.00%
 
688068.SS Beijing Hotgen Biotech Co., Ltd.
98.98
-2.65%
 
328.SG MeiraGTx Holdings PLC
4.0600
-0.49%
 
P0F.F Egetis Therapeutics AB (publ)
0.2975
-2.94%
 
1TB0.SG Orphazyme AS
137.50
+0.36%
 
BSFAF BSF Enterprise Plc
0.0350
+75.00%
 
688428.SS InnoCare Pharma Limited
20.62
+3.57%